Stay updated on PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC

Sign up to get notified when there's something new on the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page.
Latest website image capture
Clouds background image

Latest updates to the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page

  1. Check
    7 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer now displays revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-11-01T04:00:12.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    A notice about NIH websites transitioning to use the term “Super Intelligence” instead of “Artificial Intelligence” appears on the page.
    Difference
    0.7%
    Check dated 2026-10-25T04:28:07.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer displays software revision v3.7.2 instead of v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-18T04:33:19.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The site revision label in the footer changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-11T07:58:12.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    The Record History gains a new Revision: v3.7.0 entry. It also removes Revision: v3.6.6, updating the version history to reflect the latest change.
    Difference
    0.1%
    Check dated 2026-09-20T02:54:33.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    A new revision entry v3.6.6 is added to the study record history, and the previous entry v3.6.5 is removed. This updates the page's version history to reflect the latest revision.
    Difference
    0.1%
    Check dated 2026-08-30T00:19:05.000Z thumbnail image

Stay in the know with updates to PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC

Enter your email address, and we'll notify you when there's something new on the PHOEBE Trial: Pyrotinib vs Lapatinib in HER2+ MBC page.